Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -41.33% | -116.11% | -86.01% | -17.87% | -26.73% |
Total Depreciation and Amortization | 70.31% | 70.69% | 58.93% | 50.94% | 18.52% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 17.90% | 11.03% | 17.49% | 23.16% | 26.78% |
Change in Net Operating Assets | -384.55% | 83.32% | 162.46% | -117.06% | 232.42% |
Cash from Operations | -85.32% | -113.15% | -47.60% | -60.86% | -7.00% |
Capital Expenditure | -34.00% | -37.40% | -476.47% | -304.44% | -476.92% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -34.00% | -37.40% | -476.47% | -304.44% | -476.92% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 29,086.47% | -99.48% | 393.24% | -22.92% | 563.09% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 29,065.83% | -99.48% | 393.24% | -22.92% | 563.09% |
Foreign Exchange rate Adjustments | -117.86% | 90.72% | 1,319.77% | 812.77% | 657.55% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 710.53% | -123.34% | -45.03% | -61.81% | 0.90% |